ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences) today announced that Cell Cure Neurosciences has been awarded a grant of 5.34 million Shekels, approximately $1.5 million, for 2013 from Israels Office of the Chief Scientist (OCS) to help finance the development of OpRegen, a cell-based therapeutic product in development by Cell Cure Neurosciences for the treatment of age-related macular degeneration. Cell Cure Neurosciences plans for the development of OpRegen include completion of preclinical testing and filing an application to commence human clinical trials in 2014.
We thank the Israel Office of the Chief Scientist for their continuing support of stem cell research and their participation in advancing this important new application of regenerative medicine, said Charles Irving, PhD, Chief Executive of Cell Cure Neurosciences. The dry form of age-related macular degeneration is one of the leading diseases of aging and is estimated to afflict over 7.3 million people in the United States alone. We anticipate that OpRegen will make a real difference in the quality of life of the aging baby-boom generation in many industrialized countries, and hence it is a strategic investment for the world as a whole.
I join with Dr. Irving in thanking the OCS for their generous support in accelerating the advance of stem cell biology into the clinic. We are proud that the decision of the OCS also reflects on the excellence of the stem cell science of the company, in addition to the potential of the product for treating the dry form of age-related macular degeneration, said Benjamin Reubinoff, MD, PhD, Chief Scientific Officer of Cell Cure Neurosciences and Chairman of Obstetrics and Gynecology and Director of the Hadassah Human Embryonic Stem Cell Research Center at Hadassah University Medical Center, Jerusalem, Israel.
The OCS has previously provided grants to Cell Cure Neurosciences. Cell Cure Neurosciences will pay a 3.5% royalty to the OCS on revenues from OpRegen until total royalties paid equal 100% of the amount of the grant plus interest at a LIBOR rate. Historically Cell Cure Neurosciences and BioTimes other subsidiaries have raised capital, received grants, and generated revenues independently of BioTime to help fund their operations; we expect Cell Cure Neurosciences to continue to pursue such financing strategies in the future.
About Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. was established in 2005 as a subsidiary of ES Cell International Pte. Ltd. (ESI), now a subsidiary of BioTime, Inc. (NYSE MKT: BTX). Cell Cure is located in Jerusalem, Israel on the campus of Hadassah University Hospital. Cell Cure's mission is to become a leading supplier of human cell-based therapies for the treatment of retinal and neural degenerative diseases. Its technology platform is based on the manufacture of diverse cell products sourced from clinical-grade (GMP) human embryonic stem cells. Its current programs include developing cells for the treatment of macular degeneration, Parkinson's disease, and cells potentially useful in treating multiple sclerosis. Cell Cure's major shareholders include BioTime Inc., Hadasit BioHoldings Ltd. (Tel Aviv Stock Exchange: HDST), and Teva Pharmaceuticals Industries Ltd. (TEVA). Additional information about Cell Cure can be found on the web at http://www.cellcureneurosciences.com.
About BioTime, Inc
BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary PureStem cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards, the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap Sciences also markets BioTime research products and PanDaTox, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a new subsidiary being used to acquire the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine. BioTime's lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at http://www.biotimeinc.com.
Forward-Looking Statements
Read the rest here:
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief Scientist
- Stem Cells In Human Trials - September 15th, 2011 [September 15th, 2011]
- NZ Stemcell Trials - Part One - September 15th, 2011 [September 15th, 2011]
- CIRM Major Facilities Speed Stem Cell Science and Create Jobs - September 15th, 2011 [September 15th, 2011]
- Geron's Embryonic Stem Cell Clinical Trial for Spinal Cord Injury - September 15th, 2011 [September 15th, 2011]
- Hans Keirstead - Stem Cell Research Human Clinical Trials - September 15th, 2011 [September 15th, 2011]
- Stem-Cell Human Trials - September 15th, 2011 [September 15th, 2011]
- Geron: FDA Clearance for Human Clinical Stem Cell Trials - September 15th, 2011 [September 15th, 2011]
- Eric Legrand Rutgers University shout out, Listen up! - September 20th, 2011 [September 20th, 2011]
- How to Mend a Broken Heart - September 20th, 2011 [September 20th, 2011]
- Human Embryonic Stem Cell History! - September 20th, 2011 [September 20th, 2011]
- Robert Lanza - ACT - Stem cells and organ cloning interview - September 20th, 2011 [September 20th, 2011]
- Toonari Post Health News: Europe's first clinical trial using human embryonic stem cells - September 23rd, 2011 [September 23rd, 2011]
- Diabetes: Spotlight on Stem Cell Research - Ed Baetge - September 23rd, 2011 [September 23rd, 2011]
- Talking Apes being created by Science | Planet of the Apes, here we come! - September 24th, 2011 [September 24th, 2011]
- Health news: Internet use, sleep, human stem cell research - September 24th, 2011 [September 24th, 2011]
- Geron - September 24th, 2011 [September 24th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - A Father's Story - September 24th, 2011 [September 24th, 2011]
- The Frankenstein Syndrome Trailer - September 24th, 2011 [September 24th, 2011]
- Leukemia: Spotlight on Stem Cell Research - Patient Stories - September 24th, 2011 [September 24th, 2011]
- Geron Corp. Initiates First Human Study Of Embryonic Stem-Cell Therapy - September 24th, 2011 [September 24th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Yung-Wei Chi - September 24th, 2011 [September 24th, 2011]
- Stemcells come alive: Fix Mouse with severed spine ABCnews - September 24th, 2011 [September 24th, 2011]
- StemCells Gains 5% on Neural Stem Cell Trial in Spinal Cord Injury - September 24th, 2011 [September 24th, 2011]
- Stem-Cell Research on Animals - September 24th, 2011 [September 24th, 2011]
- First hESC Therapy Clinical Trial - September 24th, 2011 [September 24th, 2011]
- Stem Cell Testing on Human Subjects [Officially] Begins • NBC Nightly News • October 11th, 2010 - September 24th, 2011 [September 24th, 2011]
- Leukemia: Spotlight on Stem Cell Research - Catriona Jamieson - September 24th, 2011 [September 24th, 2011]
- First stem cell trial begins - September 24th, 2011 [September 24th, 2011]
- Parkinson's Disease: Spotlight on Stem Cell Research - Arnold Kriegstein - September 24th, 2011 [September 24th, 2011]
- Becoming a Blood Stem Cell Donor - September 24th, 2011 [September 24th, 2011]
- Stem cells might be able to reverse the effects of a heart attack. - September 24th, 2011 [September 24th, 2011]
- Horse Stem Cell Video.mp4 - September 25th, 2011 [September 25th, 2011]
- Stem cell trials to begin - September 25th, 2011 [September 25th, 2011]
- Lou Gehrig's Disease (ALS): Progress and Promise in Stem Cell Research - September 25th, 2011 [September 25th, 2011]
- Hans Keirstead - September 25th, 2011 [September 25th, 2011]
- Stem Cell Quiz - September 25th, 2011 [September 25th, 2011]
- NZ Stemcell Trials - Part Two - September 25th, 2011 [September 25th, 2011]
- Drug Trials in a Dish - September 25th, 2011 [September 25th, 2011]
- Rise and Walk - September 25th, 2011 [September 25th, 2011]
- Catriona Jamieson: Therapies Based on Cancer Stem Cells - September 27th, 2011 [September 27th, 2011]
- Vatican lending hand in adult stem cell research - September 28th, 2011 [September 28th, 2011]
- Why STEM-Enhance? - September 28th, 2011 [September 28th, 2011]
- Genetic Underpinnings of Alopecia Areata - September 29th, 2011 [September 29th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Ann Tsukamoto - September 29th, 2011 [September 29th, 2011]
- stem cell trial for leading causes of blindness - October 9th, 2011 [October 9th, 2011]
- Forbes Discusses Stem Cell Research - Video - October 13th, 2011 [October 13th, 2011]
- Bruce Conklin: Drug screening with stem cells - Video - October 13th, 2011 [October 13th, 2011]
- Human Trials of Embryonic Stem Cell Treatment Beginning - Video - October 13th, 2011 [October 13th, 2011]
- Rise and Walk - Video - October 13th, 2011 [October 13th, 2011]
- Mesenchymal Stem Cell Trials - Video - October 14th, 2011 [October 14th, 2011]
- Spinal Cord Injury: Progress and Promise in Stem Cell Research - Video - October 14th, 2011 [October 14th, 2011]
- Better Drugs Through Stem Cells - Video - October 16th, 2011 [October 16th, 2011]
- Adult Stem Cells Used To Rebuild Heart Tissue / Video - Video - October 16th, 2011 [October 16th, 2011]
- GARY RABIN- ADVANCED CELL TECHNOLOGIES 2011 - Video - October 21st, 2011 [October 21st, 2011]
- Stem cell treatment on horse a success, vet says - Video - October 21st, 2011 [October 21st, 2011]
- MAJOR EMBRYONIC STEM CELL BREAKTHROUGHS - Video - October 22nd, 2011 [October 22nd, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Stephen Huhn - Video - November 13th, 2011 [November 13th, 2011]
- Human Cloning has Begun | Playing God? - Video - November 15th, 2011 [November 15th, 2011]
- Diabetes: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video - November 15th, 2011 [November 15th, 2011]
- Brain Tumors: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video - November 15th, 2011 [November 15th, 2011]
- Double Blind Trial of Stem Cells for Heart Failure - Video - December 4th, 2011 [December 4th, 2011]
- Cardiac Stem Cell Therapy Clinical Trial - Video - December 4th, 2011 [December 4th, 2011]
- Glasgow Hospital Conducts First Stem Cell Trials on Stroke Patients - Video - December 4th, 2011 [December 4th, 2011]
- Dr Dietrich discusses the Geron stem cell trial to treat acute spinal cord injury - Video - December 4th, 2011 [December 4th, 2011]
- Stem Cell Research Today: Larry Goldstein - CIRM Science Writer's Seminar - Video - December 7th, 2011 [December 7th, 2011]
- Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video - December 22nd, 2011 [December 22nd, 2011]
- Clinical trials and stem cells: what patients should consider - Video - January 2nd, 2012 [January 2nd, 2012]
- Spare Parts for Humans: Tissue Engineers Aim for Lab-Grown Limbs, Lungs and More - Video - January 4th, 2012 [January 4th, 2012]
- CIRM Grant Writing: RFA's - Where does your Project Fit? - Video - January 5th, 2012 [January 5th, 2012]
- Prometheus and I: building new body parts from stem cells (15 Nov 2011) - Video - January 5th, 2012 [January 5th, 2012]
- News Bulletin 18 November 2011 -- The Christian Institute - Video - January 5th, 2012 [January 5th, 2012]
- The Brain on Trial: How Neuroscience Challenges the Law as We Know It - Video - January 5th, 2012 [January 5th, 2012]
- The Human Genome and Individualized Medicine - David Valle, MD - Video - January 5th, 2012 [January 5th, 2012]
- 2010 Professional of Distinction - Discovery Awards - Video - January 23rd, 2012 [January 23rd, 2012]
- Research at The Nebraska Medical Center Biologics Production Facility - Video - January 24th, 2012 [January 24th, 2012]
- ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived ... - January 30th, 2012 [January 30th, 2012]
- StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision - January 31st, 2012 [January 31st, 2012]
- $30 million donation from Boris family will help McMaster turn stem cell research into therapy - February 6th, 2012 [February 6th, 2012]
- Stem Cell Treatment For Blindness Shows Promise In Trials - February 7th, 2012 [February 7th, 2012]
- ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from ... - February 13th, 2012 [February 13th, 2012]